Hematologic Malignancies
Gyala Therapeutics S.L. focuses on acute leukemia research, with clinical activity in relapsed/refractory acute myeloid leukemia and relapsed/refractory T-cell acute lymphoblastic leukemia. Its work is centered on challenging blood cancers that require new treatment options after standard therapies have failed.
- Relapsed/Refractory Acute Myeloid Leukemia
- Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia
The sponsor’s clinical interest is directed toward high-risk hematologic disease in patients with limited therapeutic alternatives.
Cell-Based Immunotherapy
The company is active in CAR T-cell therapy, with research centered on engineered T-cell treatment for leukemia. This area reflects a focus on immune-based oncology approaches designed to target malignant blood cells.
- CAR T-Cell Therapy
- T-Cell Engineering
Its therapeutic interest lies in adoptive cellular therapy for aggressive hematologic cancers.
Oncology Safety and Tolerability
Gyala Therapeutics S.L. also concentrates on the safety and tolerability of novel oncology treatments, reflecting a clinical emphasis on treatment-related risk in patients with advanced leukemia.
- Safety Assessment
- Tolerability Evaluation
This area supports development in innovative cancer immunotherapies intended for difficult-to-treat blood malignancies.
Clinical Efficacy in Leukemia
The sponsor’s research includes assessment of clinical response in acute leukemia, with attention to remission outcomes in patients receiving advanced cellular therapy.
- Overall Response Rate
- Complete Remission
- Morphologic Leukemia-Free State
Its clinical interest is concentrated on measurable outcomes in refractory leukemia populations.
